New drug combination before surgery for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have been diagnosed with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Your cancer is stage III or IV and cannot be removed with surgery at this time.
- You have not had any previous cancer treatments like chemotherapy, radiation, or immunotherapy.
- You are generally in good health (able to care for yourself) and have adequate organ function.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs with chemotherapy, with or without a targeted therapy pill, given before surgery for advanced ovarian cancer. It aims to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests a combination of four drugs for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this new combination can shrink tumors or slow the disease.
This trial tests a combination of three targeted drugs (olaparib, durvalumab, and bevacizumab) as a first treatment for advanced ovarian cancer. It aims to shrink tumors before possible surgery, potentially improving outcomes.
Hear when a new Ovarian Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.